Review of data of Testosterone in post-menopausal women is seriously lacking--especially long-term safety data and this is worrisome as other data points to increased CVD and cancer with increasing Testosterone levels in women.
Review of the data points to poor quality of evidence dealing with DHEA in post-menopausal women with normal adrenal function. Yet if DHEA is low, which is >95% produced by adrenals in women, then how can the adrenal function be "normal". The meta-analysis found no improvement in libido and/or sexual function, and no improvement in lipids, glucose, weight... was noted. Essentially not positive or negative effects were noted. Abstract only available here, so dosage is a question.
ER beta expression and the ratio of ER alpha/ER beta is important in prognosis and effectiveness of SERM therapy like tamoxifen. This study looked at the aromatase inhibitor anastrazole as well.
women with increased gut microbiome diversity found to have increased estrogen metabolites compared to parent estrogen i.e. gut microbiome diversity in women effects estrogen metabolism.
Get article on estrogen metabolism/metabolites and their effects on the risk of breast cancer in post menopause women. This article brings to light new information: 2:16alpha estrone ratio is not a great predicted of risk, 2-OH and 4-OH metabolites can form quinone intermediates...
Post-menopause women with increased gut microbiome diversity found to be associated with increased urinary excretion of estrogen metabolites compared to parent estrogens. This relationship has been shown to be associated with a reduced breast cancer risk.
our results do not support the hypothesis that greater metabolism of oestrogen via the 2-OH pathway, relative to the 16α-OH pathway, protects against endometrial cancer. Indeed our results are more suggestive of an increase in risk, rather than a decrease, with higher levels of 2-OHE1
women with a higher 2-OHE1 : 16α-OHE1 ratio did not have a decreased risk of endometrial cancer as compared with women with a lower ratio
The findings from this first prospective epidemiological study of oestrogen metabolites and endometrial cancer are in line with results from prospective studies on breast cancer, another oestrogen-related cancer. None of the seven studies on breast cancer reported significant associations overall
On the whole, prospective epidemiological data do not support the hypothesis that the 2-hydroxyestrogen pathway is protective, and the 16α-hydroxyestrogen pathway harmful, in hormone-dependent cancers
Both 2- and 4-hydroxyestrogens are catecholestrogens, and it has been suggested that catecholestrogens increase risk of oestrogen-mediated cancers through direct genotoxic effects, rather than through stimulation of cell proliferation via binding to oestrogen receptors
the evidence is stronger for 4-hydroxyestrogens than for 2-hydroxyestrogens
a significant increase in risk of breast cancer with levels of 2-OHE1 has also been reported previously, although it was limited to hormone receptor-negative tumours
Topical hormones best evaluated via saliva and/or blood spot. Urine and particularly serum does not increase with dosing. That does not mean the topical hormone therapy is ineffective, just that serum and urine are not optimal to follow topical therapy. When looking at endogenous hormones without any therapies: serum, saliva, urine, and blood spot are equivalent.
A recent study of nine patients concluded that the urinary EMR is a good approximation for breast tissue EMR
A single study in young women not using oral contraceptives found fair correlation coefficients between urinary and plasma EMR
All of nine properly designed epidemiological studies (six prospective case-control studies and three retrospective studies) failed to show a significant relationship between urinary or circulating EMR (2OHE1/16αOHE1) and breast cancer risk
premenopausal studies on urinary EMR have suggested a potentially weak inverse relationship, associations were not significantly different compared with postmenopausal or overall combined studies
at present, there is no evidence that the EMR can predict breast cancer risk
This study finds no difference between the sexes as it relates to testosterone and inflammatory cytokines. They only found a correlation with CRP as it relates to oxidized LDL.